Hormone Refractory Prostate Cancer Terminated Phase 2 Trials for Docetaxel (DB01248)

Back to Hormone Refractory Prostate Cancer

Also known as: Hormone Refractory Prostate Cancer Disease / Hormone-Refractory Prostate Cancer / Castration-resistant prostate cancer / Hormone refractory prostate cancer (disorder)

IndicationStatusPhase
DBCOND0030609 (Hormone Refractory Prostate Cancer)Terminated2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01194960TroVax® In Subjects With Hormone Refractory Prostate Cancer (HRPC)Treatment
NCT00525408A Study of Mycobacterium w Plus Docetaxel for Hormone Refractory Metastatic Prostate CancerTreatment
NCT00313482PII Trial of Docetaxel/Prednisone w/Sargramostim for HRPCTreatment